AlphaMol Science Ltd

AlphaMol combines computational methods and in-house cutting-edged biotechnology, aiming at advancing pre-clinical GPCR drug discovery in an ultimately efficient way. AlphaMol has invented three first-in-class PCC within 3-9 months, which usually takes 5-7 years to achieve via traditional way. G protein-coupled receptors (GPCRs) are the most important drug targets. About 40% of the marketed drugs are targeting at GPCRs. Almost all important diseases are related to GPCRs directly, including Alzheimer's disease, cancer, diabetes, pain, depression, auto-immune, infections and many others. AlphaMol established a dedicated GPCR-purposed platform for drug discovery. In the GPCR-DOCK 2021 global contest, AlphaMol defeated Google's AlphaFold2 for the five nominated targets, with 60% higher accuracy. In 2022, AlphaMol obtained the best outstanding award in NVIDIA Inception contest for startups. In the same year, both co-founders of AlphaMol, Prof. Shuguang Yuan and Prof. Horst Vogel were in the list of "top 2%" scientists in the world.